Transparency data

Research and methodology group

Updated 30 July 2025

© Crown copyright 2025

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/uk-national-screening-committee-register-of-interests/research-and-methodology-group

This register records declarations made by members in respect of interests they have that are relevant to the remit of the UK NSC’s research and methodology group (RMG).

Prof Sian Taylor-Phillips (Chair)

Dr Ania Bobrowska

  • employed by Costello Medical, a consultancy that has delivered projects in evidence synthesis and the analysis, interpretation and communication of clinical and health economic data for the UK NSC
  • listed on a grant for Policy Support Fund at University of Warwick on a methodology project with the aim ‘to redesign the methods used by the UK National Screening Committee when evaluating new screening tests using surrogate outcomes’ (Costello Medical is paid for Dr Bobrowska’s time (0.5 day per week) to work on the project)

Dr Adam Brentnall

  • employed by King’s College London Cancer Prevention Trials Unit for consultancy related to developing and supporting an algorithm to invite people to the NHS Galleri Trial through NHS DigiTrials (indirect income from Grail through King’s)
  • co-Investigator on TRANSFORM prostate cancer screening trial
  • statistician on BEST4 screening trial (investigating capsule sponge as a screening test for oesophageal cancer)
  • Medical Research Council funding for statistical methodology PhD related to multi-cancer detection tests (MCDs)
  • royalty payments through Cancer Research UK for commercial use of the IBIS (Tyrer-Cuzick) breast cancer risk algorithm
  • employed by Queen Mary University of London
  • research funding from Cancer Research UK (CRUK), Prostate Cancer UK, National Institute of Health Research (NIHR), Breast Cancer Now and Barts Charity
  • genetic epidemiologist/statistician on the National Institute for Health and Care Excellence (NICE) familial ovarian cancer guideline committee
  • standing member of Cancer Research UK’s expert review panel on early detection and diagnosis trials, behavioural, health systems and health economics research
  • research in a variety of areas related to cancer screening and prevention, including:
    • investigating the effectiveness of gene testing for breast and ovarian cancer prevention
    • risk-stratified breast cancer screening
    • artificial intelligence (AI) methods for breast cancer screening
    • prostate cancer detection AI methods
    • multi-cancer early detection tests
    • molecular triage tests for HPV screening
    • alternative methods for HPV sampling
  • as principal investigator (PI) or co-PI, engaged with others working in cancer screening and prevention, including those who sell breast density software (Volpara), genetic testing (Myriad Genetics), multi-cancer early detection tests (Grail), academics at other research institutions and colleagues who aim to develop biomarker panels for use in cancer screening, including in the molecular epidemiology laboratory at the Wolfson Institute of Population Health, Queen Mary University of London

Prof Karla Hemming

  • none

Prof Joan Morris

  • none

Prof Katherine Payne

  • member of Cancer Research UK Early Detection and Diagnosis Research Committee
  • co-applicant on 2 grants related to the UKNSC RMG:

    • Title: Reducing inequalities in cancer early detection through interdisciplinary research and community partnerships: ACED Inequalities Theme Phase I Programme. Funder: CRUK International Alliance for Cancer Early Detection (ACED) – Programme Award Phase 1 – 2024 Application. Date: July 2025 for 12 months

    • Title: Early Detection using Information Technology in Health (EDITH). Funder: NIHR Health Technology Assessment (HTA) Call Title: 23/60 The use of artificial Intelligence for imagine interpretation in breast cancer screening. Date: May 2025 for 48 months

Prof Jo Waller

  • undertakes research funded by various charities and commercial organisations, currently including CRUK, Breast Cancer Now, Office for Health Improvement and Disparities, Grail Bio Ltd and the NHS Accelerated Access Collaborate (this funding is awarded to King’s College London)
  • principal investigator on a research grant awarded by GRAIL Bio UK to King’s College London (former employer) and novated to Queen Mary University of London (current employer)

Prof Olivia Wu

  • None
Back to top